We are honored to have Professor Jean-Yves Blay join our Medical Advisory Board.
Prof. Blay, an internationally recognized medical oncologist and key opinion leader in sarcoma cancer serves as the General Director of the Centre Léon Bérard, Cancer Research Center of Lyon, France.
He is also President of the French Federation of Cancer Centers (UNICANCER), Director of the French national sarcoma reference network NETSARC+ (comprising 26 centers), and Director of the European Reference Network for rare adult cancers, EURACAN (which includes 106 centers across 26 countries).
Prof. Blay has co-authored over 1,000 peer-reviewed articles and scientific publications.
Prof. Blay brings deep clinical knowledge and firsthand experience with the latest advancements in oncology, which will help guide our strategy in advancing our lead program, MQI-201, into new indications and then into the clinic.
« The efficiency of MQI-201 drug candidate in highly aggressive syngeneic sarcoma model is really impressive. Such a pharmacological potency associated with the safety profile of this anti-TRPV6 antibody opens the way to a clinical development of MQI-201 aiming at obtaining a fast-track registration under an Orphan Drug Designation in various sarcoma indications which urgently need innovative therapeutic solutions. French and European sarcoma clinical experts community will be excited to conduct such a study as soon as possible. » said Pr. JY Blay
